Hematologic Oncology

The FDA has approved bosutinib for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia who are intolerant or who have become resistant to prior therapy.

Lenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patients with multiple myeloma.

The FDA approved Marqibo to treat patients with Philadelphia chromosome-negative adult acute lymphoblastic leukemia following at least two relapses or failed treatment.

Ponatinib, an oral multikinase inhibitor, generated significant responses in more than 50% of patients with certain chronic myeloid leukemia subtypes.

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.

Dr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure

Bortezomib represented a major discovery in cancer research and has helped some patients achieve a complete pathological response and live longer.

The FDA approved carfilzomib for patients with multiple myeloma who have received at least two prior lines of therapy.

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.

Cancer drugs once deemed too toxic for humans have earned a second chance at therapeutic utility, in part because of a reversal in the usual progression of medical research.

A closer look at the hematology pipeline where there are multiple promising studies in progress for hematologic malignancies, including lymphoma, leukemia, and multiple myeloma.

ODAC voted 11-0 in support of carfilzomib as a new treatment option for patients with multiple myeloma, despite side effect concerns raised by the FDA.

One of my teachers in medical school was fond of saying, "Internal medicine isn't sexy." Hematology/ oncology is no exception to this rule. Certainly, it is not as glamorous as cardiology or as hands-on as gastroenterology.

Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

To learn more about how photopheresis can help patients fight the symptoms of CTCL, OncologyLive spoke with Dennis Parenti, MD, vice president of Clinical Affairs for Therakos.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.